

Minutes of the **Somerset ICS Medicines Optimisation Committee** held via Microsoft Teams, on **Wednesday, 10<sup>th</sup> February 2021**.

Present:	Dr Andrew Tresidder (AT)	Chair, CCG GP Patient Safety Lead
	Mark Ashley (MA)	Chief Pharmacist, Somerset NHSFT
	Steve Du Bois (SDB)	Chief Pharmacist, Somerset NHSFT
	Shaun Green (SG)	Deputy Director of Clinical Effectiveness and Medicines Management, CCG
	Michael Lennox (ML)	LPC Representative
	Sam Morris (SM)	Medicines Manager, CCG
	Andrew Prowse (AP)	Chief Pharmacist and Controlled Drugs Accountable Officer, YDH NHS FT
	Zoe Talbot-White (ZTW)	Prescribing Technician, CCG

## **1 INTRODUCTIONS & MEMBERSHIP**

AT welcomed everyone to the first meeting of the Somerset ICS Medicines Optimisation Committee

## **2 REGISTER OF MEMBERS' INTERESTS**

- 2.1 The Somerset ICS Medicines Optimisation Committee received the Register of Members' Interests relevant to its membership.

There were the following amendments to the Register: AT – Non-Financial – Trade purchaser of flower essence combinations to be given away. The Somerset ICS Medicines Optimisation Committee noted the Register of Members' Interests.

## **3 DECLARATIONS OF INTEREST RELATING TO ITEMS ON THE AGENDA**

- 3.1 Under the CCG's arrangements for managing conflicts of interest, any member making a declaration of interest is able to participate in the discussion of the particular agenda item concerned, where appropriate, but is excluded from the decision-making and voting process if a vote is required. In these circumstances, there must be confirmation that the meeting remains quorate in order for voting to proceed. If a conflict of interest is declared by the Chairman, the agenda item in question would be chaired by a nominated member of the Somerset ICS Medicines Optimisation Committee.

There were no declarations of interest relating to items on the agenda.

**4 Draft TORs – SIMO will initially be a subcommittee of the SPF until ICS structures are formalised.**

**4.1 Discuss roles SIMO will take over from SPF eg. Medicines Value High Cost Drugs**

**SPF & SIMO**

SPF currently acts as a conduit to get everyone's voice heard around medicines, shared care and formulary. Additional roles currently include improving governance, high cost drugs, horizon scanning and advising other parts of system of big changes (launch of DOAC & biosimilars).

Moving forward the request from the national team is to think about how we position medicines optimisation teams in the new ICS structure. We are currently a draft ICS so structures and legislation are in discussion.

Implementation will occur by April 22, although at the moment there is no chief pharmacist across the system so there is no one to be held accountable for the deadlines.

SIMO will be a separate committee to look specifically at system wide medicine optimisation rather than replace SPF. SIMO will take some workload from SPF to get the most value out of both committees and enable them to work better.

The chief pharmacists currently have limited capacity due to the Covid-19 vaccine programme however this is likely to be an issue for quite some time so will try to make full use of this committee to help shape the future of pharmacy across the system.

Awaiting ICS structure of committees but we will champion continuation of PAMM, SPF and SIMO.

**Membership**

SIMO discussed future committee membership and concluded that there should be a representative and specific voice of PCN-GP based pharmacy included.

Request that the PCNs elect a candidate to sit on the SIMO committee.

**Action: SG**

SIMO also discussed the pros and cons of having a Pharmacy Technician representative.

This idea has been put on hold as it doesn't seem essential at present and will be discussed again at a future meeting.

**Agenda items.**

Agenda items and membership need to be detailed on the Terms Of Reference.

Agenda items should focus on digital platforms & systems, workforce and pathways.

SIMO will give delegated authority to other committees/ lead people to develop and present their medicines optimisations strategies, and hold them to account for implementation.

Workforce issues to be added to a system wide risk register rather than individual Trust registers.

#### **4.2 Discuss Integration and Pharmacy Transformation Plans**

SG thanked everyone for their contributions.

Feedback from NHS England was that the plan is too CCG centric and there are gaps that must be filled around what we need.

Share business cases for posts that haven't been filled.

**Action: All**

The plan will have to go to the ICS board and we need to make a stronger case and more collaborative approach.

Separate providers need to take away and come back with further thoughts and developments.

Look at draft and give Trust/ LPC perspective for March.

**Action: All**

#### **4.3 Discuss Community Pharmacy Contractual Developments**

The NHS Discharge Medicines Service (DMS) will go live from 15<sup>th</sup> February. YDH have been given an electronic platform that they will soft pilot in April and roll out after testing.

T&S NHS FT will be using a fully electronic version as that was the only option available due to having such a lean team. More resources are needed in Somerset NHS FT.

SIMO to follow up the need for more resources as part of the workforce plan.

**Action: All-Ongoing**

SG highlighted that to begin with the service should only be used for most at risk patients or with the most changes to avoid overwhelming community pharmacies.

#### **4.4 Discuss ICS consultation**

Not discussed. Leave on agenda for next meeting.

#### **5 Somerset IMPO plan NHSE feedback**

Discussed as part of 4.2.

#### **6 Somerset Workforce NHSE plan feedback**

Feedback from the Somerset Workforce NHSE plan was that it was one of the most honest plans as it acknowledged that we have a problem and need to do something, however it wasn't ambitious or transformational enough. It didn't address the problem of having a lean and under-invested system.

The People Board of Somerset has agreed in principle to adopt and create a system wide pharmacy work stream, including securing funding for a dedicated PMO. ML is liaising with the People Board of Somerset and the leaders of the key work force group (Jane Grey & Ollie Fletcher) to get this

plan put into action.

Trusts agreed to be part of the wider plan, however felt they still needed a dedicated work force group for pharmacy.

Meet with People Board and Jane & Ollie and report back into SIMO.

**Action: ML**

SG suggested the possible use of the regional £10k funding to help facilitate this, ML also has a £11k funding which he declared however the People Board of Somerset will self-fund, if they do adopt.

ML has been working with the 7 LPCs across the South West and other key stakeholders to arrange a community pharmacy emergency workforce summit.

Keep SIMO updated with progress of the workforce summit.

**Action: ML**

## **6.1 Discuss use of regional £10k funding**

Discussed possible uses for the funding, yet to decide on an appropriate use.

SG confirmed that the CCG is happy to give Zoë's time to support meeting.

AT showed an advert for recruiting GPs in Somerset. SIMO thought it was something we should be doing to recruit pharmacists in Somerset. ML has a quote to do the same for pharmacists (around £10k), so this may be a possible use for the money.

Leave on agenda for next meeting.

## **7 Partners – 2021 Medicines Optimisation priorities**

### **7.1 LPC**

Not discussed. Leave on agenda for next meeting.

### **7.2 YDH**

Not discussed. Leave on agenda for next meeting.

### **7.3 SomersetFT**

Not discussed. Leave on agenda for next meeting.

### **7.4 CCG**

Not discussed. Leave on agenda for next meeting.

## **8 Somerset System Support contacts**

Not discussed. Leave on agenda for next meeting.

## **9 Future Standing Items for agenda**

### **9.1 Risks**

Not discussed. Leave on agenda for next meeting.

**9.2 Regional Medicines Value Work Stream**

Not discussed

**9.3 Feedback from Each Leads Priority Areas eg. AMR**

This will be a standing item on the agenda.

Specialist area leads will be encouraged to share enthusiasm and expertise by being invited to present strategies to SIMO.

Invite Anthony Zorzi (TST NHS TF) for specialty presentation on antimicrobials in April.

**Action: SG**

Decide who to invite from YDH NHS FT.

**Action: AP**

**10 Any other business**

**10.1 System High Cost Drugs Processes**

Not Discussed. Leave on agenda for next meeting.

**10.2 Covid-19 Vaccine Programme**

SG thanked everyone for delivery their work on the delivery of the Covid-19 vaccine programme and the pharmacy input. He asked for the continued support as it is going well in Somerset.

AT fully endorsed SG comments.

**DATE OF NEXT MEETINGS**

14<sup>th</sup> April 2021

9<sup>th</sup> June 2021

11<sup>th</sup> August 2021

13<sup>th</sup> October 2021

8<sup>th</sup> December 2021